Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

NCT03971799 is registered in ClinicalTrials.gov with Center for International Blood and Marrow Transplant Research as lead sponsor.

NCT NCT03971799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03971799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Center for International Blood and Marrow Transplant Research
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 8, 2020
Completion date
December 31, 2039
Enrollment
52 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia